📖
Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a MyD88-dependent manner.
Fu Z, Jackson-Patel V, Farrand K, Dabb AR, Lin X, Liu E, Ashoorzadeh A, Smaill JB, Hermans IF, Patterson AV

Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a MyD88-dependent manner.

Medicine & Health Published 2026 Verification Pending

Overview & Synopsis

Open access biomedical research article published in J Immunother Cancer.

Indexed from repository: PubMed Central (pmc.ncbi.nlm.nih.gov)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a MyD88-dependent manner.
Author / Organization Fu Z, Jackson-Patel V, Farrand K, Dabb AR, Lin X, Liu E, Ashoorzadeh A, Smaill JB, Hermans IF, Patterson AV
Subject & Discipline J Immunother Cancer
Categories Medicine & Health
Publication Year 2026
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website PubMed Central (pmc.ncbi.nlm.nih.gov)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-40318
Original Source Link Visit Source Page on pmc.ncbi.nlm.nih.gov »